Skip to main content
  1. Right Decisions
  2. Maternity & Gynaecology Guidelines
  3. Maternity
  4. Back
  5. Common obstetric problems, maternity assessment
  6. Antepartum haemorrhage (APH) (1036)
Important: please update your RDS app to version 4.7.3 Details with newsletter below.

Please update your RDS app to v4.7.3

We asked you in January to update to v4.7.2.  After the deployment planned for 27th February, this new update will be needed to ensure that you are able to download RDS toolkits even when the RDS website is not available. We will wait until as many users as possible have downloaded the new version before switching off the old system for app downloads and moving entirely to the new approach.

To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. 

To update to the latest release:

 On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.

On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.

Right Decision Service newsletter: February 2025

Welcome to the February 2025 update from the RDS team

1.     Next release of RDS

 

A new release of RDS is planned (subject to outcomes of current testing) for week beginning 24th February. This will deliver:

 

  • Fixes to mitigate the recurring glitches with the RDS admin area and the occasional brief user interface outages which have arisen following implementation of the new distributed technology infrastructure in December 2024.

 

  • Capability to embed content from Google calendar, Google Maps, Daily Motion, Twitter feeds, Microsoft Stream into RDS pages.

 

  • Capability to include simple multiplication in RDS calculators.

 

The release will also incorporate a number of small fixes, including:

  • Exporting of form within Medicines Sick Day Guidance in polypharmacy toolkit
  • Links to redundant content appearing in search in some RDS toolkits
  • Inclusion of accordion headers alongside accordion text in search result snippets.
  • Feedback form on mobile app.
  • Internal links on mobile app version of benzo tapering tool

 

We will let you know when the date and time for the new release are confirmed.

 

2.     New RDS developments

There is now the capability to publish toolkits on the web with left hand side navigation rather than tiles on the homepage. To use this feature, turn on the “Toggle navigation panel” option at the top of the Page settings menu at toolkit homepage level – see below. Please note that publication to downloadable mobile app for this type of navigation is still under development.

The Benzodiazepine tapering tool (https://rightdecisions.scot.nhs.uk/benzotapering) is now available as part of the RDS toolkit for the national benzodiazepine prescribing guidance developed by the Scottish Government Effective Prescribing team. The tool uses this national guidance developed with a wide-ranging multidisciplinary group. This should be used in combination with professional judgement and an understanding of the needs of the individual patient.

3.     Archiving and version control and new RDS Search and Browse interface

Due to the intensive work Tactuum has had to undertake on the new technology infrastructure has pushed back the delivery dates again and some new requirements have come out of the recent user acceptance testing. It now looks likely to be an April release for the search and browse interface. The archiving and version control functionality may be released earlier. We’ll keep you posted.

4.     Statistics

At the end of January, Olivia completed the generation of the latest set of usage statistics for all RDS toolkits. If you would like a copy of the stats for your toolkit, please contact Olivia.graham@nhs.scot .

 

5.     Review of content past its review date

We have now generated reports of all RDS toolkit content that has exceeded its review date by 6 months or more. We will be in touch later this month with toolkit owners and editors to agree the plan for updating or withdrawing out of date content.

 

6.     Toolkits in development

Some important toolkits in development by the RDS team include:

  • National CVD prevention pathways – due for release end of March 2025.
  • National respiratory pathways, optimal cancer diagnostic pathways and cancer prehabilitation pathways from the Centre for Sustainable Delivery. We will shortly start work on the national cancer referral pathways, first version due for release via RDS around end of June 2025.
  • HIS Quality of Care Review toolkit – currently in final stages of quality assurance.

 

The RDS team and other information scientists in HIS have also been producing evidence summaries for the Scottish Government Realistic Medicine team, to inform development of national guidance around Procedures of Limited Clinical Value. This guidance will in due course be translated into an RDS toolkit.

 

7. Training sessions for new editors (also serve as refresher sessions for existing editors) will take place on the following dates:

  • Friday 28th February 12-1 pm
  • Tuesday 11th March 4-5 pm

 

To book a place, please contact Olivia.graham@nhs.scot, providing your name, organisation, job role, and level of experience with RDS editing (none, a little, moderate, extensive.)

 

To invite colleagues to sign up to receive this newsletter, please signpost them to the registration form  - also available in End-user and Provider sections of the RDS Learning and Support area.   If you have any questions about the content of this newsletter, please contact his.decisionsupport@nhs.scot  If you would prefer not to receive future newsletters, please email Olivia.graham@nhs.scot and ask to be removed from the circulation list.

With kind regards

 

Right Decision Service team

Healthcare Improvement Scotland

 

 

Antepartum haemorrhage (APH) (1036)

Warning
Please report any inaccuracies or issues with this guideline using our online form

Definition: bleeding from or in to the genital tract, occurring from 24+0 weeks of pregnancy and prior to birth of the baby.

APH complicated 3-5% of pregnancies – leading cause of perinatal and maternal mortality worldwide.

Risk Factors for APH include:

APH and placental abruption in a previous pregnancy

Threatened miscarriage earlier in their pregnancy

Placenta praevia

Pre-eclampsia

FGR

Polyhydramnios

PPROM

Smoking

Multiple pregnancy

Drug misuse

Advanced maternal age

ART

Causes for APH include:

Unexplained

Placenta praevia

Placental abruption

Uterine rupture

Vasa praevia

Trauma

Cervical lesions

Infection

Malignancy

It is recognised that the volume of blood lost is often underestimated as blood loss may be concealed. It is important to assess for signs of clinical shock as well as fetal compromise or fetal demise as important indicators of volume depletion.

Prompt assessment of maternal and/or fetal compromise is key to establishing if urgent intervention is necessary and will guide your management.

APH Definitions:

Spotting – staining, streaking or blood spotting noted on underwear or sanitary protection.

Minor Haemorrhage – blood loss <50ml that has settled

Major Haemorrhage – blood loss of 50-1000ml, with no signs of clinical shock

Massive Haemorrhage – blood loss >1000ml and/or signs of clinical shock

Recurrent APH – episodes of APH on more than one occasion

Spotting/Minor APH

  • record an accurate, detailed history
    • include onset, amount of bleeding, associated pain, recent intercourse, smear history, associated shortness of breath or dizziness, presence of fetal movements
    • risk factors for placental abruption/praevia should also be sought
  • Record MEOWS – blood pressure, heart rate, respiratory rate, temperature
  • Record urinalysis
  • Gentle abdominal palpation and assessment of fundal height as well as uterine activity
  • Auscultate fetal heart and commence CTG (if over 26 weeks) – if unable to locate FHR with Doppler then USS should be utilised
  • Maternal Rhesus status should be noted
  • Review previous USS reports for documentation of placental site

Speculum Examination/Digital Vaginal Examination

  • Vaginal examination should not be performed until placental site is established
  • In cases of placenta praevia digital vaginal examination should be avoided Placenta Praevia guideline
  • Can be useful to identify cervical dilatation or cause for APH in lower genital tract
  • If clinically suspicious cervix refer to management of cervical abnormalities in pregnancy guideline
  • HVS should be performed if appropriate

Maternal Investigations

  • Should be performed to assess the extent and physiological consequences of APH and will depend on amount of bleeding
  • In minor APH a FBC and G&S should be performed. A coagulation screen is not indicated unless platelet count is abnormal.  BOS Guideline
  • Kleihauer test should be performed in Rhesus D – negative mothers to quantify fetomaternal haemorrhage in order to gauge the dose of anti-D immunoglobulin required. Anti-d

Management

  • Management will depend on severity of bleeding/cause/maternal and fetal compromise
  • Involve senior obstetric consultant/clinician early if concerns
  • Consider IV access (16G) if clinically appropriate
  • Consider antenatal corticosteroid therapy for fetal lung maturation – refer to relevant guidelines
  • All women with APH heavier than spotting and women with ongoing bleeding should remain in hospital at least until bleeding has settled
  • Women presenting with spotting who are no longer bleeding and where placenta praevia has been excluded can go home if initial clinical assessment is reassuring with appropriate consideration to patient’s geographically location.
  • In women with APH >37 weeks gestation consider expediting delivery
  • Following a single episode of APH or recurrent episodes thought to be from a cervical ectropion, subsequent antenatal care need not be altered.
  • Following APH from placental abruption or unexplained causes, the pregnancy should be reclassified in Badgernet as High Risk and antenatal care should be consultant-led with serial growth scans, at least until subsequent growth scans demonstrate normal fetal growth and there is no further risk of APH.

Recurrent APH (more than 1 episode)

  • If recurrent APH, including from unexplained causes, then the pregnancy should be classified in Badgernet as High Risk and antenatal care should be consultant-led with serial growth scans.

Major/Massive Antepartum Haemorrhage

Aims of management:

  • RESUSCITATION
  • DELIVERY and management of Third Stage
  • CORRECT COAGULOPATHY

 

Resuscitation:

  • Resuscitation of the mother is paramount and should be prioritised prior to establishing fetal condition
  • GET HELP – obstetric/anaesthetic/neonatal/haematology
  • Major Obstetric Haemorrhage #2222
  • ABC approach
    • Left lateral tilt
    • Airway = secure airway
    • Breathing
      • apply oxygen - non-rebreathing mask, 15L/min
      • commence pulse oximetry
    • Circulation
      • gain IV access x 2 (16G);
      • Obtain bloods including FBC/Coagulation Screen (including fibrinogen)/Kliehauer/Urea & Electrolytes – send as URGENT and alert laboratory. Consider venous blood gas.
      • Crossmatch as per blood ordering schedule – consider group specific or O negative blood if unable to wait for fully crossmatched blood
      • Commence IV fluids – crystalloid up to 2L; colloid up to 1.5L
      • Continuous pulse and blood pressure recording
      • Consider catheter insertion and monitor urine output hourly
      • Record observations on MOEWS chart
      • Keep the patient warm
    • Assess fetus – CTG/USS

Decide on Delivery

  • Delivery may be needed to control haemorrhage
  • Women with APH and associated maternal and/or fetal compromise are required to be delivered immediately
  • In the presence of maternal and/or fetal compromise delivery should be by Caesarean section with obstetric consultant present (consideration of anaesthetic consultant presence if maternal compromise)
  • Anticipate postpartum haemorrhage – pph link
  • Administer Magnesium Sulphate if gestation <30+0 for fetal neuroprotection. This should not delay delivery if there is evidence of maternal compromise.

Correct Coagulopathy:

  • Disseminated intravascular coagulation (DIC) should be considered
  • Coagulation screen and fibrinogen should be assessed – use near patient testing if available and send samples as URGENT or– alert laboratory.
  • Early liaison with Haematology is paramount
  • Consideration of Fresh Frozen Plasma/Cryoprecipitate

Editorial Information

Last reviewed: 31/12/2021

Next review date: 31/07/2025

Author(s): Julie Murphy.

Version: 1

Approved By: Obstetrics Clinical Guideline Group

Document Id: 1036

References

Antepartum Haemorrhage Green Top Guideline No. 63 RCOG 2011

Practical Obstetric Multi-Professional Training (PROMPT)